6 June 2025 -- Pennsylvania, US -- PCI Pharma Services, a world leading global contract development and manufacturing organization (CDMO), will use the BIO International Convention, June 16-19 in Boston, as a platform to introduce its new purpose-built facility for large-scale sterile fill-finish operations at its campus in nearby Bedford, NH.

4 June 2025 -- Bubendorf, Switzerland -- CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.

2 June 2025 -- Maryland, US -- At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation today announced significant further advances in ultra-high sensitivity 4D-Proteomics with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor technology further boosts the extreme sensitivity of timsTOF Ultra PASEF methods for key biological and clinical research problems with very low sample amounts.

2 June 2025 -- Maryland, US -- At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows.

2 June 2025 — London, UK — In just two weeks, the second edition of the London Biotechnology Show (LBS) returns to ExCeL London on 18–19 June, bringing together one of the most influential gatherings in the global biotechnology calendar. The event promises cutting-edge science, transformative innovation, and forward-thinking leadership.

30 May 2025 -- Koelnmesse, Germany -- From 4–5 June, thousands of industry professionals will gather in Cologne for the 38th edition of Chemspec Europe – the leading marketplace for fine and speciality chemicals in pharma, life sciences, and industry.

30 May 2025 -- Maryland, US -- For the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides.

30 May 2025 -- Maryland, US -- At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation launched timsMetabo™, a peak-performance 4D-Metabolomics™ mass spectrometer delivering unprecedented sensitivity, separation power and annotation confidence for small molecules, further enhanced by the novel TIMS ‘MoRE’ scan-mode.

World Vaccine Congress Europe will host 2500+ attendees, 280 speakers, 150 exhibitors and start-ups over the course of 4 days. With a multitude of tracks, the congress will cover everything vaccine related from start-to-finish from 13-16 October 2025.

Join global biotech and pharma leaders in Singapore, September 9–10, 2025, for the third edition of Asia Bio Partnering Forum.

22 May 2025 -- Koelnmesse, Germany -- From 4–5 June, the international fine and speciality chemicals industry will gather at Koelnmesse, Germany, for the 38th edition of Chemspec Europe – the sector’s leading sourcing hub for chemical innovation in pharma and industry. Set in vibrant Cologne, near some of Europe’s largest chemical parks and pharma sites, the event provides a perfect gateway to connect with international professionals in chemical development and manufacturing.

21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab) as an option for preventing bleeding episodes in people 12 years of age and older, weighing at least 35kg, with severe haemophilia B (congenital factor IX deficiency, factor 9 activity less than 1%), without factor 9 inhibitors (anti-factor antibodies).